




|                         |                   |   |
|-------------------------|-------------------|---|
| <b>Name</b>             | Sang-Jun Ha       |  |
| <b>Country</b>          | Republic of Korea |   |
| <b>Organization</b>     | Yonsei University |   |
| <b>Current Position</b> | Professor         |   |

### Educational Background

|           |  |
|-----------|--|
| 1998-2001 | Ph.D., Division of Molecular and Life Sciences, POSTECH, Pohang, Korea |
| 1996-1998 | M.S., Department of Life Science, POSTECH, Pohang, Korea               |
| 1992-1996 | B.S., Department of Biochemistry, Yonsei University, Seoul, Korea      |

### Professional Experiences

|              |   |
|--------------|---|
| 2019-current | Professor, Yonsei University, Seoul, Korea                              |
| 2014-2019    | Associate Professor, Yonsei University, Seoul, Korea                    |
| 2009-2014    | Assistant Professor, Yonsei University, Seoul, Korea                    |
| 2007-2009    | Research Associate, Emory University School of Medicine, Atlanta, USA   |
| 2004-2007    | Post-doctoral fellow, Emory University School of Medicine, Atlanta, USA |
| 2001-2004    | Post-doctoral fellow, POSTECH, Pohang, Korea                            |

### Professional Organizations

|                |   |
|----------------|---|
| 2022 – Present | Executive Board Member, Korean Cancer Association                               |
| 2022 – 2023    | General Manager, Korean Society of Biochemistry and Molecular Biology           |
| 2021 – 2023    | Chair, Scientific Committee, Korean Society of Gene and Cell Therapy            |
| 2021 – 2022    | Chair, Education & PR committee, Korean Association of Immunologists            |
| 2017 – Present | Member, Young Korean Academy of Science and Technology (Y-KAST)                 |
| 2015 – 2016    | Chair, International Cooperation Committee, Korean Association of Immunologists |
| 2015 – Present | Executive Board Member, Korean Association of Immunologists                     |

### Main Scientific Publications

1. Deletion of PD-1 destabilizes the lineage identity and metabolic fitness of tumor-infiltrating regulatory T cells. **Nature Immunology** 2023 Jan;24(1):148-161
2. Viral coinfection promotes tuberculosis immunopathogenesis by type I IFN signaling-dependent impediment of Th1 cell pulmonary influx. **Nature Communications** 2022 Jun 7;13(1):3155
3. Disproportional enrichment of Foxp3+CD4+ regulatory T cells shapes a suppressive tumor microenvironment and provokes anti-PD-1 resistance in head and neck squamous cell carcinoma. **Clinical and Translational Medicine** 2022 Mar;12(3):e753
4. Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer. **Journal for ImmunoTherapy of Cancer** 2021 Dec;9(12):e002780
5. Dysregulation of TFH-B-TRM lymphocyte cooperation is associated with unfavorable anti-PD-1 responses in EGFR-mutant lung cancer. **Nature Communications** 2021 Oct 18;12(1):6068
6. Tumor-infiltrating regulatory T-cell accumulation in the tumor microenvironment is mediated by IL33/ST2 signaling. **Cancer Immunology Research** 2020 Nov;8(11):1393-1406